Page last updated: 2024-11-03

risperidone and Chemical Dependence

risperidone has been researched along with Chemical Dependence in 34 studies

Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.

Research Excerpts

ExcerptRelevanceReference
"A long-term randomized trial of unstable patients with schizophrenia found no benefit of long-acting injectable (LAI) risperidone over oral treatment in preventing or delaying time to psychiatric hospitalizations or on clinical outcomes."9.19Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia. ( Krystal, JH; Leatherman, SM; Lew, RA; Liang, MH; Rosenheck, RA; Thwin, SS; Valley, D, 2014)
"The purpose of this study is to compare the efficacy of olanzapine and risperidone for the acute treatment of first-episode schizophrenia patients with cannabis use disorders."9.15Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes. ( Kane, J; McCormack, J; Miller, R; Napolitano, B; Robinson, DG; Sevy, S; Sunday, S, 2011)
"This study aimed to compare the efficacy of long-acting risperidone and zuclopenthixol in subjects with schizophrenia and substance abuse."9.12Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. ( Alamo, C; Jiménez-Arriero, MA; López-Muñoz, F; Martínez, I; Ponce, G; Rubio, G, 2006)
"A long-term randomized trial of unstable patients with schizophrenia found no benefit of long-acting injectable (LAI) risperidone over oral treatment in preventing or delaying time to psychiatric hospitalizations or on clinical outcomes."5.19Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia. ( Krystal, JH; Leatherman, SM; Lew, RA; Liang, MH; Rosenheck, RA; Thwin, SS; Valley, D, 2014)
"The purpose of this study is to compare the efficacy of olanzapine and risperidone for the acute treatment of first-episode schizophrenia patients with cannabis use disorders."5.15Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes. ( Kane, J; McCormack, J; Miller, R; Napolitano, B; Robinson, DG; Sevy, S; Sunday, S, 2011)
"Among patients with chronic schizophrenia who avoid use of illicit drugs, olanzapine was more effective than other antipsychotics as reflected by longer time to all-cause discontinuation, but illicit substance abuse attenuated this advantage, reinforcing the need for concurrent substance abuse treatment."5.13The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. ( Canive, JM; Davis, SM; Hsiao, JK; Khan, A; Lieberman, JA; McEvoy, JP; McGee, M; Miller, DD; Reimherr, F; Stroup, TS; Swanson, JW; Swartz, MS; Wagner, HR, 2008)
"This study aimed to compare the efficacy of long-acting risperidone and zuclopenthixol in subjects with schizophrenia and substance abuse."5.12Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. ( Alamo, C; Jiménez-Arriero, MA; López-Muñoz, F; Martínez, I; Ponce, G; Rubio, G, 2006)
"This 12-month, prospective, observational study investigated factors associated with symptomatic remission (total YMRS score < or =12) and full clinical recovery (sustained reduction in CGI-BP-S overall score) in bipolar disorder during treatment with atypical antipsychotics (predominantly olanzapine, risperidone and quetiapine; alone or in combination with a psychotropic such as lithium or valproate) in actual clinical practice."3.76Twelve-month prospective, multinational, observational study of factors associated with recovery from mania in bipolar disorder in patients treated with atypical antipsychotics. ( Badr, MG; D'yachkova, Y; Dikeos, D; Fábián, Z; Harrison, G; Hudiţă, C; Okasha, T; Pesek, MB; Tapia-Paniagua, G; Treuer, T; Yang, F, 2010)
" Patients aged 2 18 years who received an initial prescription for olanzapine, risperidone, quetiapine or amisulpride between April 1 and September 30, 2003; and had an ICD-10-coded diagnosis of schizophrenia were included."3.74Atypical antipsychotic therapy for treatment of schizophrenia in Hong Kong Chinese patients--a cost analysis. ( Hui, HY; Law, WL; You, JH; Young, WM, 2007)
"Risperidone was associated with more detrimental subjective experiences compared with paliperidone ER and placebo (p < ."2.77Different safety profiles of risperidone and paliperidone extended-release: a double-blind, placebo-controlled trial with healthy volunteers. ( Chung, YC; Kim, MG; Oh, KY; Park, MS; Park, TW; Yang, JC; Yoon, KS, 2012)
" Based on recent criteria for pediatric populations, patients were considered "at risk for adverse health outcome" if they met at least 1 of the following criteria: (1) > or = 85th BMI percentile plus presence of 1 or more negative weight-related clinical outcomes, or (2) > or = 95th BMI percentile."2.73Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. ( Arango, C; Cifuentes, A; Fraguas, D; Giráldez, M; Laita, P; Merchán-Naranjo, J; Moreno, D; Parellada, M; Ruiz-Sancho, A, 2008)
"Risperidone was compared to clozapine, olanzapine, perphenazine, quetiapine and ziprasidone."2.58Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse. ( Siegfried, N; Stein, DJ; Temmingh, HS; Williams, T, 2018)
"In patients with a psychotic disorder, substance abuse is a major problem."2.45Differences in efficacy on substance abuse between risperidone and clozapine supports the importance of differential modulation of dopaminergic neurotransmission. ( de Haan, L; Machielsen, MW, 2009)
"Little is known about the influence of substance use on side effects."1.62The Influence of Substance Use on Side Effects of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Psychosis. ( Alisauskiene, R; Gjestad, R; Johnsen, E; Jørgensen, HA; Kroken, RA; Løberg, EM, 2021)
"Risperidone LAT was typically used with recommended age and diagnostic groups."1.37Risperidone long-acting therapy prescribing patterns and their impact on early discontinuation of treatment in a large Medicaid population. ( Becker, MA; Boaz, TL; Constantine, RJ; Howe, AM; Robst, J, 2011)

Research

Studies (34)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's5 (14.71)18.2507
2000's15 (44.12)29.6817
2010's10 (29.41)24.3611
2020's4 (11.76)2.80

Authors

AuthorsStudies
Thurstone, C1
Loh, R1
Foreman, K1
Thurstone, CA1
Wolf, C1
Drevin, G1
Picard, N1
Jousset, N1
Briet, M1
Abbara, C1
Aras, N1
Alisauskiene, R1
Johnsen, E1
Gjestad, R1
Kroken, RA1
Jørgensen, HA1
Løberg, EM1
Temmingh, HS1
Williams, T1
Siegfried, N1
Stein, DJ1
Leatherman, SM1
Liang, MH1
Krystal, JH1
Lew, RA1
Valley, D1
Thwin, SS1
Rosenheck, RA2
Mohamed, S1
Lin, H1
Swartz, M1
McEvoy, J1
Stroup, S1
Saglam, O1
Bahsi, R1
Akkoca, Y1
Filik, L1
Fraguas, D1
Merchán-Naranjo, J1
Laita, P1
Parellada, M1
Moreno, D1
Ruiz-Sancho, A1
Cifuentes, A1
Giráldez, M1
Arango, C1
Khantzian, EJ1
Albanese, MJ2
Rothermel, B1
Poustka, L1
Banaschewski, T1
Becker, K1
Dikeos, D1
Badr, MG1
Yang, F1
Pesek, MB1
Fábián, Z1
Tapia-Paniagua, G1
Hudiţă, C1
Okasha, T1
D'yachkova, Y1
Harrison, G1
Treuer, T1
Parikh, SV1
LeBlanc, SR1
Ovanessian, MM1
Machielsen, MW1
de Haan, L1
Boaz, TL1
Constantine, RJ1
Robst, J1
Becker, MA1
Howe, AM1
Sevy, S1
Robinson, DG1
Sunday, S1
Napolitano, B1
Miller, R1
McCormack, J1
Kane, J1
Yoon, KS1
Park, TW1
Yang, JC1
Kim, MG1
Oh, KY1
Park, MS1
Chung, YC1
Green, AI1
Burgess, ES1
Dawson, R1
Zimmet, SV1
Strous, RD1
Gasquet, I1
Haro, JM1
Novick, D1
Edgell, ET1
Kennedy, L1
Lepine, JP1
Lambert, M1
Conus, P1
Lubman, DI1
Wade, D1
Yuen, H1
Moritz, S1
Naber, D1
McGorry, PD1
Schimmelmann, BG1
Rubio, G1
Martínez, I1
Ponce, G1
Jiménez-Arriero, MA1
López-Muñoz, F1
Alamo, C1
Bellack, AS1
Brown, CH1
Thomas-Lohrman, S1
Smelson, DA2
Tunis, SL1
Nyhuis, AW1
Faries, DE1
Kinon, BJ1
Ascher-Svanum, H1
Law, WL1
Hui, HY1
Young, WM1
You, JH1
Swartz, MS1
Wagner, HR1
Swanson, JW1
Stroup, TS1
McEvoy, JP1
Reimherr, F1
Miller, DD1
McGee, M1
Khan, A1
Canive, JM1
Davis, SM1
Hsiao, JK1
Lieberman, JA1
Bacher, NM1
Kaup, BA1
Roy, A1
Roy, M1
Misra, L1
Kofoed, L2
Iyo, M1
Sekine, Y1
Matsunaga, T1
Tsukamoto, T1
Takei, N1
Mori, N1
Misra, LK1
Fuller, W1
Solhkhah, R1
Finkel, J1
Hird, S1
Gupta, N1
Basu, D1
Isbister, GK1
Whyte, IM1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Risperidone Long-Acting for Alcohol and Schizophrenia Treatment (R-LAST)[NCT00130923]Phase 495 participants (Actual)Interventional2005-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Average Over Time of Frequency of Drinking Days (Used to Evaluate Treatment Efficacy)

Frequency of drinking days is obtained each week retrospectively as the number of drinking days during the prior week (assessed using the Timeline Followback). Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months

Interventiondrinking days per week (Number)
Risperidone Long Acting Injectable (LAI)2.84
Oral Risperidone Aka Risperdal3.46

Average Over Time of Global Functioning (Used to Evaluate Treatment Efficacy)

A rater assesses social, occupational and psychological functioning on a hypothetical continuum of mental health - illness (using Global Assessment of Functioning); scores range from 100 to 1, where higher values represent a better outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months

Interventionordinal severity of impairment (Number)
Risperidone Long Acting Injectable (LAI)50.8
Oral Risperidone Aka Risperdal49.9

Average Over Time of Positive and Negative Symptoms (Used to Evaluate Treatment Efficacy)

A rater assesses positive and negative symptoms of schizophrenia using a 30-item scale (Positive and Negative Symptom Score) Scores range from 30 to 210, where higher values represent a worse outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months

Interventionordinal severity of symptoms (Number)
Risperidone Long Acting Injectable (LAI)78.2
Oral Risperidone Aka Risperdal75.5

Average Over Time of Severity of Illness and Global Improvement (Used to Evaluate Treatment Efficacy)

A rater assesses the severity of illness and global impression using a scale from 1 to 7 (Clinical Global Impression), where higher values represent a worse outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months

Interventionordinal unit of severity (Number)
Risperidone Long Acting Injectable (LAI)4.02
Oral Risperidone Aka Risperal3.96

Change Over Time in Frequency of Heavy Drinking Days (Used to Evaluate Treatment Efficacy)

Frequency of heavy drinking days is obtained each week retrospectively as the number of heavy drinking days during the prior week (assessed by the Timeline Followback Scale). A heavy drinking day is defined as 4 or more drinks per day for a female and 5 or more drinks per day for a male. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months

Interventionheavy drinking days per week (Number)
Risperidone Long Acting Injectable (LAI)-.11
Oral Risperidone Aka Risperal.68

Number of Participants With Medication Adherence

Number of participants with medication adherence (defined as taking medication at least 75% of the days in the treatment period). (NCT00130923)
Timeframe: 6 months

InterventionParticipants (Count of Participants)
Risperidone Long Acting Injectable (LAI)43
Oral Risperidone Aka Risperdal28

Reviews

2 reviews available for risperidone and Chemical Dependence

ArticleYear
Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse.
    The Cochrane database of systematic reviews, 2018, Jan-22, Volume: 1

    Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Diagnosis, Dual (Psychiatry); Humans; Mental Disor

2018
Differences in efficacy on substance abuse between risperidone and clozapine supports the importance of differential modulation of dopaminergic neurotransmission.
    Psychopharmacology bulletin, 2009, Volume: 42, Issue:4

    Topics: Antipsychotic Agents; Clozapine; Humans; Psychotic Disorders; Receptors, Dopamine D1; Receptors, Dop

2009

Trials

9 trials available for risperidone and Chemical Dependence

ArticleYear
Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia.
    The Journal of nervous and mental disease, 2014, Volume: 202, Issue:1

    Topics: Administration, Oral; Adult; Aged; Antipsychotic Agents; Chronic Disease; Drug Administration Schedu

2014
Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia.
    The Journal of nervous and mental disease, 2015, Volume: 203, Issue:7

    Topics: Adolescent; Adult; Aged; Alcoholism; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Comorbi

2015
Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics.
    The Journal of clinical psychiatry, 2008, Volume: 69, Issue:7

    Topics: Adolescent; Benzodiazepines; Blood Glucose; Body Mass Index; Child; Diagnostic and Statistical Manua

2008
Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes.
    Psychiatry research, 2011, Aug-15, Volume: 188, Issue:3

    Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Body Weight; Female; Humans; Longitudinal

2011
Different safety profiles of risperidone and paliperidone extended-release: a double-blind, placebo-controlled trial with healthy volunteers.
    Human psychopharmacology, 2012, Volume: 27, Issue:3

    Topics: Adult; Analysis of Variance; Antipsychotic Agents; Chi-Square Distribution; Cognition; Double-Blind

2012
Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity.
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2006, Volume: 51, Issue:8

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Clopenthixol; Comorbidity; Delayed-Action Preparation

2006
Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use.
    Journal of clinical psychopharmacology, 2006, Volume: 26, Issue:6

    Topics: Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Patient Dropouts; Risperidone; Schizophre

2006
The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.
    Schizophrenia research, 2008, Volume: 100, Issue:1-3

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Comorbidity; Dibenzothiazepines; Doub

2008
Safety and efficacy of risperidone in substance abusers with psychosis.
    The American journal on addictions, 2001,Spring, Volume: 10, Issue:2

    Topics: Adult; Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Female; Humans; Male; Middle Aged

2001

Other Studies

23 other studies available for risperidone and Chemical Dependence

ArticleYear
Program Evaluation to Aid Choice of Aripiprazole or Risperidone for Hospitalized Adolescents with Cannabis Use Disorder and Psychosis.
    Journal of child and adolescent psychopharmacology, 2023, Volume: 33, Issue:8

    Topics: Adolescent; Adolescent, Hospitalized; Antipsychotic Agents; Aripiprazole; Humans; Marijuana Abuse; P

2023
Pitfalls and challenges associated with phenoconversion in forensic toxcicology.
    Forensic science international. Genetics, 2021, Volume: 51

    Topics: Adult; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Forensic Toxicology; Heterozygote; Humans;

2021
A Case of Self-Cannibalism: An Extremely Rare Type of Self-Mutilation With Multiple Risk Factors.
    The Journal of nervous and mental disease, 2021, 04-01, Volume: 209, Issue:4

    Topics: Adult; Antipsychotic Agents; Antisocial Personality Disorder; Cannibalism; Electroconvulsive Therapy

2021
The Influence of Substance Use on Side Effects of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Psychosis.
    Substance use & misuse, 2021, Volume: 56, Issue:12

    Topics: Adult; Benzodiazepines; Female; Humans; Male; Olanzapine; Piperazines; Psychotic Disorders; Quetiapi

2021
Risperidone-induced hepatotoxicity in a patient addicted to synthetic cannabinoid.
    European journal of gastroenterology & hepatology, 2016, Volume: 28, Issue:3

    Topics: Adult; Antipsychotic Agents; Cannabinoids; Chemical and Drug Induced Liver Injury; Drug Substitution

2016
Self-medication, bipolar disorders, and stimulant dependence.
    The Journal of clinical psychiatry, 2009, Volume: 70, Issue:6

    Topics: Affect; Antipsychotic Agents; Bipolar Disorder; Central Nervous System Stimulants; Comorbidity; Dibe

2009
[Bipolar disorders as co-morbidity in childhood and adolescence--underdiagnosed or overinterpreted? Therapy of a 14-year-old boy with hyperkinetic conduct disorder and hypomania].
    Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie, 2010, Volume: 38, Issue:2

    Topics: Adolescent; Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; A

2010
Twelve-month prospective, multinational, observational study of factors associated with recovery from mania in bipolar disorder in patients treated with atypical antipsychotics.
    The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2010, Volume: 11, Issue:4

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Comorbidity; Diagnostic and Statisti

2010
Advancing bipolar disorder: key lessons from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2010, Volume: 55, Issue:3

    Topics: Anticonvulsants; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Anxiety Disorders;

2010
Risperidone long-acting therapy prescribing patterns and their impact on early discontinuation of treatment in a large Medicaid population.
    The Journal of clinical psychiatry, 2011, Volume: 72, Issue:8

    Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Comorbidity; Delayed-Action Pre

2011
Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone.
    Schizophrenia research, 2003, Mar-01, Volume: 60, Issue:1

    Topics: Adult; Aged; Alcohols; Antipsychotic Agents; Cannabis; Clozapine; Female; Humans; Male; Middle Aged;

2003
Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study.
    International clinical psychopharmacology, 2005, Volume: 20, Issue:4

    Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Demography; Depr

2005
The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis.
    Acta psychiatrica Scandinavica, 2005, Volume: 112, Issue:2

    Topics: Adult; Antipsychotic Agents; Australia; Benzodiazepines; Cohort Studies; Disease Progression; Female

2005
Psychometric characteristics of role-play assessments of social skill in schizophrenia.
    Behavior therapy, 2006, Volume: 37, Issue:4

    Topics: Adult; Antipsychotic Agents; Clozapine; Comorbidity; Crime Victims; Diabetes Mellitus, Type 2; Femal

2006
Atypical antipsychotic therapy for treatment of schizophrenia in Hong Kong Chinese patients--a cost analysis.
    International journal of clinical pharmacology and therapeutics, 2007, Volume: 45, Issue:5

    Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; China; Cost of Illness; Cost-Benefit Anal

2007
Combining risperidone with standard neuroleptics for refractory schizophrenic patients.
    The American journal of psychiatry, 1996, Volume: 153, Issue:1

    Topics: Antipsychotic Agents; Diagnosis, Dual (Psychiatry); Drug Therapy, Combination; Humans; Risperidone;

1996
Risperidone and neuropsychological test performance in cocaine-withdrawn patients.
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 1997, Volume: 42, Issue:4

    Topics: Adult; Antipsychotic Agents; Cocaine; Humans; Male; Neuropsychological Tests; Risperidone; Substance

1997
Risperidone treatment of methamphetamine psychosis.
    The American journal of psychiatry, 1997, Volume: 154, Issue:8

    Topics: Drug Administration Schedule; Humans; Male; Methamphetamine; Middle Aged; Psychoses, Substance-Induc

1997
Methamphetamine-associated obsessional symptoms and effective risperidone treatment: a case report.
    The Journal of clinical psychiatry, 1999, Volume: 60, Issue:5

    Topics: Adult; Dopamine Antagonists; Humans; Male; Methamphetamine; Obsessive-Compulsive Disorder; Psychoses

1999
Treatment of inhalant abuse with risperidone.
    The Journal of clinical psychiatry, 1999, Volume: 60, Issue:9

    Topics: Administration, Inhalation; Adult; Gasoline; Humans; Male; Petroleum; Psychoses, Substance-Induced;

1999
Possible risperidone-induced visual hallucinations.
    Journal of the American Academy of Child and Adolescent Psychiatry, 2000, Volume: 39, Issue:9

    Topics: Adolescent; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Diagnosis, Du

2000
Does risperidone reduce concomitant substance abuse in cases of schizophrenia?
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2001, Volume: 46, Issue:9

    Topics: Adult; Codeine; Comorbidity; Diagnosis, Dual (Psychiatry); Ephedrine; Humans; Male; Risperidone; Sch

2001
Atypical presentation of risperidone toxicity.
    Veterinary and human toxicology, 2002, Volume: 44, Issue:2

    Topics: Adult; Antipsychotic Agents; Diagnosis, Differential; Drug Overdose; Female; Humans; Male; Miosis; R

2002